MedTrace Logo

A Phase 1, Single and Multiple Dose Study of TAK-137

NCT02322606 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-11-26

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of TAK-137 in healthy male subjects.

Conditions

  • Healthy Japanese Adult Male

Interventions

DRUG

TAK-137 5 mg tablet, TAK-137 placebo tablet

DRUG

TAK-137 5 mg tablet, TAK-137 placebo tablet

DRUG

TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet

DRUG

TAK-137 5mg tablet, TAK-137 placebo tablet

DRUG

TAK-137 5 mg tablet, TAK-137 placebo tablet

DRUG

TAK-137 5mg tablet, TAK-137 placebo tablet

Sponsors & Collaborators

Principal Investigators

  • General Manager · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322606 on ClinicalTrials.gov